Focal segmental glomerulosclerosis (FSGS) Clinical Trials

6 recruitingLast updated: July 25, 2026

There are 6 actively recruiting focal segmental glomerulosclerosis (fsgs) clinical trials across 24 countries. Studies span Phase 2, Phase 3, Not Applicable, Phase 1. Top locations include Beijing, Beijing Municipality, China, Barcelona, Spain, Chisinau, Moldova. Updated daily from ClinicalTrials.gov.


Focal segmental glomerulosclerosis (FSGS) Trials at a Glance

6 actively recruiting trials for focal segmental glomerulosclerosis (fsgs) are listed on ClinicalTrialsFinder across 6 cities in 24 countries. The largest study group is Phase 2 with 2 trials, with the heaviest enrollment activity in Beijing, Barcelona, and Chisinau. Lead sponsors running focal segmental glomerulosclerosis (fsgs) studies include Bio-Thera Solutions, Dimerix Bioscience Pty Ltd, and Everest Medicines (China) Co.,Ltd..

Browse focal segmental glomerulosclerosis (fsgs) trials by phase

Treatments under study

About Focal segmental glomerulosclerosis (FSGS) Clinical Trials

Looking for clinical trials for Focal segmental glomerulosclerosis (FSGS)? There are currently 5 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Focal segmental glomerulosclerosis (FSGS) trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Focal segmental glomerulosclerosis (FSGS) clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 16 of 6 trials

Recruiting
Phase 2

Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of EVER001 in Participants With Selected Proteinuric Glomerular Diseases

Focal segmental glomerulosclerosis (FSGS)IgA Nephropathy (IgAN)Minimal Change Disease (MCD)
Everest Medicines (China) Co.,Ltd.45 enrolled2 locationsNCT07614477
Recruiting
Not Applicable

SLIT ABS: Study on Patients With Autoimmune Podocytopathy

Focal segmental glomerulosclerosis (FSGS)Nephrotic Syndrome Due to Idiopathic Membranous NephropathyMinimal Change Nephrotic Syndrome+1 more
Meyer Children's Hospital IRCCS50 enrolled14 locationsNCT07516964
Recruiting
Phase 2Phase 3

A Clinical Study of BAT4406F Injection in Patients With Minimal Change Disease/Focal Segmental Glomerulosclerosis

Focal segmental glomerulosclerosis (FSGS)Minimal Change Disease (MCD)
Bio-Thera Solutions192 enrolled1 locationNCT07499700
Recruiting
Phase 1

A Phase 1 Trial to Evaluate the Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of VIS171 in Participants With Autoimmune Disease(s)

Systemic Lupus Erythematosus (SLE)Alopecia Areata (AA)Immune-mediated Focal Segmental Glomerulosclerosis (FSGS)
Otsuka Pharmaceutical Development & Commercialization, Inc.30 enrolled6 locationsNCT06799520
Recruiting

Raman Spectroscopy Diagnosis of Kidney Diseases

Focal segmental glomerulosclerosis (FSGS)IgA Nephropathy (IgAN)Membranous Nephropathy+1 more
Zunsong Wang200 enrolled1 locationNCT06760845
Recruiting
Phase 3

A Pivotal Phase 3 Study of the Efficacy and Safety of DMX-200 in Patients With focal segmental glomerulosclerosis (FSGS) Who Are Receiving an angiotensin II receptor blocker (ARB)

Focal segmental glomerulosclerosis (FSGS)
Dimerix Bioscience Pty Ltd286 enrolled20 locationsACTRN12622000066785